ESMO 2026: The Next Wave of Oncology Innovation
- Home
- esmo conference 2026
- esmo 2026 preview content
ESMO 2026: Spotlight on the Latest Oncology Developments
ESMO 2026 is set to provide important evidence across the oncology treatment landscape, with several presentations expected to address key questions around treatment efficacy, sequencing, and the potential to influence treatment strategies and the competitive landscape. The congress will reflect broader shifts across oncology, including intensifying competition among Antibody-Drug Conjugates (ADCs), growing clinical validation of bispecific immune therapies, the shift toward perioperative and curative-intent treatment, and greater reliance on biomarker-defined treatment selection and sequencing. Several presentations will also evaluate whether emerging therapies can improve upon or potentially replace established standards of care.
The ESMO 2026 programme will feature a broad portfolio of clinical data across tumor types, with Late-Breaking Abstracts (LBAs), Presidential Symposium presentations, Proffered Papers, and Rapid Oral sessions providing the key platforms for the most relevant late-stage and potentially practice-influencing findings. The Presidential Symposia alone will feature 12 Late-Breaking Abstracts, spanning major areas including lung, genitourinary, gastrointestinal, melanoma, and gynaecologic cancers, while additional LBAs will be presented through Proffered and Rapid Oral sessions.
Against this broad programme, this preview selectively highlights the top five abstracts across five major oncology groupings: Lung Cancer; Breast Cancer; Genitourinary and Gynaecologic Cancers; Gastrointestinal, Biliary and Neuroendocrine Cancers; and Melanoma and Other Cancers. The selected studies represent approximately 25 high-priority abstracts and are prioritized based on the potential to influence clinical practice, validate novel therapeutic platforms, challenge existing standards of care, expand treatment into earlier disease settings, or establish new biomarker- and mechanism-driven treatment strategies. Particular emphasis is placed on Phase III readouts, mature survival analyses, novel ADCs and bispecific, perioperative approaches, biomarker-defined treatment, and studies with clear competitive or development implications.
Tumor-type Watch lists
Lung Cancer
|
Lung Cancer | |||||
|
Abstract Type |
Abstract No. |
Abstract Title |
Presenter |
Session |
Why it matters |
|
Proffered paper |
LBA66 |
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous NSCLC: randomized phase 3 OptiTROP-Lung06 study |
Caicun Zhou |
October 25, 2026; 10:15–11:45 (CEST) |
Tests an ADC replacing the conventional platinum chemotherapy backbone in an immunotherapy combination |
|
Proffered paper |
LBA67 |
Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study |
Li Zhang |
October 25, 2026; 10:15–11:45 (CEST) |
Final OS data for a TROP2 ADC in post-TKI EGFR-mutated NSCLC. |
|
Proffered Paper 1 |
LBA68 |
Phase 3 study of sigvotatug vedotin (SV) vs docetaxel in previously treated non-squamous Non-small Cell Lung Cancer (NSCLC) |
Peters |
October 25, 2026; 10:15–11:45 (CEST) |
Integrin β6 ADC; OS/PFS update adds to earlier topline and supports a Phase III with pembrolizumab in 1L |
|
Presidential Symposium II |
LBA5 |
Efficacy and safety of divarasib versus sotorasib or adagrasib in previously treated KRAS G12C-mutated advanced NSCLC |
Ferdinandos Skoulidis |
October 25, 2026 |
Directly compares a next-generation KRAS G12C inhibitor against established same-class therapies to define the preferred targeted treatment |
|
Presidential Symposium II |
LBA6 |
Osimertinib plus savolitinib versus platinum –pemetrexed in EGFR-mutated, MET-overexpressed and/or amplified advanced NSCLC after osimertinib: SAFFRON phase 3 primary results |
Lu Shun |
October 25, 2026; 16:30 – 18:15 (CEST) |
Tests a precision resistance strategy combining continued EGFR blockade with MET inhibition after osimertinib progression |
Breast Cancer
|
Breast Cancer | |||||
|
Abstract Type |
Abstract No. |
Abstract Title |
Presenter |
Session |
Why it matters |
|
Proffered paper 1 |
LBA23 |
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer |
Sara A. Hurvitz |
October 25, 2026 |
Tests whether T-DXd can bring an ADC-based strategy into the curative-intent setting of HER2-low early breast cancer. |
|
Proffered paper 2 |
LBA51 |
Results From KEYNOTE-B49: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (Pembro) vs Placebo (Pbo) Plus Chemotherapy (CT) in Participants (Pts) With HR+/HER2− Advanced Breast Cancer |
Hope Rugo |
October 24, 2026; 08:30 – 10:00 (CEST) |
Adding pembrolizumab to chemotherapy can extend the role of immunotherapy into HR-positive/HER2-negative advanced breast cancer |
|
Proffered paper 2 |
LBA14 |
A double-blind placebo-controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): overall survival results of the CCTG/BCT MA.40/FINER Study |
Andrew Redfern |
October 24, 2026; 08:40–08:50 (CEST) |
OS data for an AKT inhibitor–endocrine therapy combination |
|
Proffered paper 1 |
LBA50 |
PANKU-Breast01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic (LA/M) Hormone Receptor-Positive/HER2-negative (HR+/HER2-) Breast Cancer (BC) |
Dennis Slamon |
October 24, 2026; 08:30– 08:35 (CEST) |
Evaluates a later-line strategy for HR+/HER2 -metastatic breast cancer after multiple endocrine and targeted therapies |
|
Rapid oral session |
4639RO |
Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01 |
Ying Fan |
October 26, 2026; 10:15 – 10:20 (CEST) |
Mature OS data for a TROP2-directed ADC in previously treated metastatic TNBC |
Genitourinary and Gynaecologic Cancers
|
Genitourinary and Gynaecologic Cancers | |||||
|
Abstract Type |
Abstract No. |
Abstract Title |
Presenter |
Session |
Why it matters |
|
Rapid oral session |
2219RO |
Patient-reported outcomes (PROs) in men with mCSPC and HRR gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study |
Azad |
October 23, 2026; 13:30–15:00 (CEST) |
PRO data for a PARP inhibitor + ARPI combination in HRR-altered mCSPC, assessing whether efficacy gains are maintained without compromising quality of life |
|
Proffered paper |
4734O |
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin |
Chatzkel |
October 23, 2026; 13:30–15:00 (CEST) |
ctDNA analysis of perioperative EV + pembrolizumab in MIBC, exploring molecular residual disease as a tool for treatment response and risk stratification. |
|
Presidential Symposium I |
LBA2 |
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial |
Thomas B. Powles |
October 25, 2026; 08:30 – 10:00 (CEST) |
Tests perioperative ADC + immunotherapy intensification against conventional treatment in cisplatin-ineligible MIBC |
|
Proffered paper |
LBA42 | Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: primary analysis of the phase 2 dose optimization part of the REJOICE-Ovarian01 study |
Isabelle L. Ray-Coquard |
October 19, 2026; 14:45 – 16:15 (CEST) |
Primary dose-optimization data for a CDH6-directed ADC in platinum-resistant ovarian cancer, supporting Phase III development of a novel targeted approach |
|
Proffered paper |
LBA56 |
NRG-GY020: Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk (HIR) Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer |
Floor Backes |
October 24, 2026 |
Tests whether pembrolizumab can enhance radiation in early-stage dMMR endometrial cancer, extending immunotherapy into curative-intent treatment |
Gastrointestinal, Biliary and Neuroendocrine
|
Gastrointestinal, Biliary and Neuroendocrine | |||||
|
Abstract Type |
Abstract No. |
Abstract Title |
Presenter |
Session |
Why it matters |
|
Proffered paper 1 |
2875O |
Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study |
Manish A. Shah |
October 23, 2026; 10:15–11:45 (CEST) |
Tests pembrolizumab added to definitive chemoradiotherapy in locally advanced esophageal/GEJ cancer |
|
Presidential Symposium II |
LBA7 |
CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second- or later-line (2L+) advanced or metastatic Claudin 18.2 positive gastroesophageal carcinoma (GEC) |
Rui-Hua Xu |
October 25, 2026; 16:30 – 18:15 (CEST) |
Final Phase III OS data for a CLDN18.2-targeted ADC in previously treated advanced gastric/GEJ/esophageal adenocarcinoma |
|
Rapid oral session |
LBA79 |
Zanidatamab + chemotherapy ± tislelizumab for first-line (1L) HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: second interim analysis from HERIZON-GEA-01 |
Kohei Shitara |
October 25, 2026 |
Mature efficacy and HRQoL data for a next-generation HER2-targeted bispecific antibody plus immunotherapy in first-line HER2-positive gastroesophageal cancer |
|
Proffered paper |
LBA77 |
Arcotatug Tavatecan (IBI343/TAK-921) versus treatment of physician's choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study |
Kohei Shitara |
October 23, 2026; 13:30-15:00 (CEST) |
First interim efficacy data for a CLDN18.2-directed ADC in heavily pretreated HER2-negative gastric/GEJ cancer |
|
Presidential Symposium II |
LBA8 |
Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1) |
Jian Zhou |
October 25, 2026; 16:30 – 18:15 CEST |
Interim OS data testing an ivonescimab-based immunotherapy combination against durvalumab plus chemotherapy in first-line advanced BTC |
|
Rapid oral session |
2394RO |
Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma |
Tao Zhang/ Zhenyu Lin |
October 23, 2026; 16:15 – 17:45 CEST |
Updated efficacy data for a novel triplet in first-line extrapulmonary NEC. |
Melanoma and Other Cancers
|
Melanoma and Other Cancers | |||||
|
Abstract Type |
Abstract No. |
Abstract Title |
Presenter |
Session |
Why it matters |
|
Proffered paper |
2071O |
STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (PBO) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma |
Dirk Schadendorf |
October 23, 2026; 16:15–17:45 (CEST) |
Tests a BRAF/MEK inhibitor triplet against pembrolizumab alone in first-line BRAF V600-mutant melanoma |
|
Presidential Symposium I |
LBA1 |
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) |
Georgina V. Long |
October 24, 2026, at 16:30 (CEST) |
Phase III validation of an individualized mRNA neoantigen therapy added to pembrolizumab in adjuvant melanoma |
|
Rapid oral session |
4156RO |
Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM study |
Xue Hou |
26 October 2026; 10:15–11:45 (CEST) |
Interim data for a PD-1/VEGF bispecific + chemotherapy in first-line recurrent/metastatic thymic carcinoma |
|
Presidential Symposium III |
LBA9 |
Risvutatug rezetecan versus gemcitabine/docetaxel in heavily pretreated relapsed/refractory osteosarcoma |
Lu Xie |
26 October 2026 |
Tests B7-H3 ADC activity in osteosarcoma and the cross-tumour reproducibility of the ris-van der Rez platform beyond SCLC |
|
Presidential Symposium III |
LBA10 |
Phase 3 randomized non-inferiority trial assessing reduced-frequency immune checkpoint inhibitor dosing in responding patients |
Gwenaëlle Gravis |
26 October 2026 |
Tests whether response-adapted immunotherapy de-escalation can maintain efficacy while reducing treatment burden |
In conclusion, ESMO 2026 is expected to be a key inflection point for the oncology treatment landscape, with several datasets capable of influencing clinical practice, competitive positioning, and future drug development. The selected studies will test whether next-generation ADCs, bispecifics, immunotherapies, and biomarker-driven strategies can move beyond incremental benefit to challenge established standards of care. Collectively, these readouts will help identify the therapies and platforms most likely to shape the next generation of oncology treatment.
Executive Summary
A Pre-congress Preview of Practice-Shaping, First-in-Class, and Late-Breaking Data Across Major Cancer Types